AstraZeneca has reported positive top-line results from the phase three studies deployed to investigate the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) to treat hospitalised adult patients with complicated intra-abdominal infections (cIAI).

CAZ-AVI is composed of cephalosporin (ceftazidime), an established treatment for serious bacterial infections and a next-generation non-beta lactam beta-lactamase inhibitor (avibactam).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The RECLAIM-1 and RECLAIM-2 phase three studies have evaluated the safety and efficacy of CAZ-AVI, which is under development with AstraZeneca to treat wide range of gram-negative bacterial infections that are becoming resistant to antibiotics.

"These results…highlight the potential for CAZ-AVI to provide a much-needed new treatment option for serious and life-threatening intra-abdominal infections."

AstraZeneca chief medical officer and global medicines development executive vice-president Briggs Morrison said: "We are very encouraged by these results which highlight the potential for CAZ-AVI to provide a much-needed new treatment option for serious and life-threatening intra-abdominal infections, especially where antibiotic resistance poses a threat to treatment."

In the studies, CAZ-AVI was administered intravenously as a two hour infusion (2,000mg / 500mg) plus metronidazole, compared to having meropenem administered intravenously as a 30 minute infusion (1g), in hospitalised adult patients with complicated intra-abdominal infections.

Following the agreement with US Food and Drug Administration (FDA) and European Medicines Agency (EMA), the date from the RECLAIM-1 and RECLAIM-2 studies were analysed as a single-pooled dataset.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

CAZ-AVI has reached the objective of statistical non-inferiority compared to meropenem in both the phase three studies.

In addition, studies are initiated for CAZ-AVI in complicated urinary tract infections (cUTI), nosocomial pneumonia and for the treatment of cIAI and cUTI patients with ceftazidime-resistant infections.

AstraZeneca, along with Actavis’ wholly owned subsidiary Forest Laboratories, is developing CAZ-AVI. AstraZeneca holds the global rights to commercialise CAZ-AVI, while Forest holds the rights for North America.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact